Edward D Huey1, Nicole Armstrong, Parastoo Momeni, Jordan Grafman. 1. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Cognitive Neuroscience Section, Building 10, Room 7D43, MSC 1440, Bethesda, MD 20892-1440, USA. hueye@ninds.nih.gov
Abstract
BACKGROUND: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. OBJECTIVE: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. METHODS: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. CONCLUSIONS: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.
BACKGROUND: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. OBJECTIVE: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. METHODS: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. CONCLUSIONS: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.
Authors: A Delacourte; Y Robitaille; N Sergeant; L Buée; P R Hof; A Wattez; A Laroche-Cholette; J Mathieu; P Chagnon; D Gauvreau Journal: J Neuropathol Exp Neurol Date: 1996-02 Impact factor: 3.685
Authors: V Buée Scherrer; P R Hof; L Buée; B Leveugle; P Vermersch; D P Perl; C W Olanow; A Delacourte Journal: Acta Neuropathol Date: 1996 Impact factor: 17.088
Authors: J A Gogos; M Morgan; V Luine; M Santha; S Ogawa; D Pfaff; M Karayiorgou Journal: Proc Natl Acad Sci U S A Date: 1998-08-18 Impact factor: 11.205
Authors: M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti Journal: Proc Natl Acad Sci U S A Date: 1998-06-23 Impact factor: 11.205
Authors: Rogier A Feis; Mark J R J Bouts; Jessica L Panman; Lize C Jiskoot; Elise G P Dopper; Tijn M Schouten; Frank de Vos; Jeroen van der Grond; John C van Swieten; Serge A R B Rombouts Journal: Neuroimage Clin Date: 2018-07-17 Impact factor: 4.881
Authors: Rogier A Feis; Mark J R J Bouts; Jessica L Panman; Lize C Jiskoot; Elise G P Dopper; Tijn M Schouten; Frank de Vos; Jeroen van der Grond; John C van Swieten; Serge A R B Rombouts Journal: Neuroimage Clin Date: 2019-03-01 Impact factor: 4.881